Literature DB >> 2406204

Residual immunity of athymic NCr/Sed nude mice and the xenotransplantation of human tumors.

V Silobrcic1, A L Zietman, J R Ramsay, H D Suit, R S Sedlacek.   

Abstract

This study assessed the residual immunity possessed by NCr/Sed (nu/nu) athymic nude mice and examined strategies to reduce it in order to enhance the transplantability of human tumors for experimentation. Adult (8-week-old) female mice had fewer T cells (11%) and more B and NK (asialo-GM1-positive [ASGM1+]) cells in their spleen than euthymic (nu/+) controls. The number of phenotypically mature T cells increased with age, peaking at 16 weeks. ASGM1+ cells also increased in number over time, although the NK-activity decreased after 12 weeks. B cells remained relatively constant in number. Athymic NCr/Sed nude mice displayed reactivity against a human squamous carcinoma xenograph (FaDu), in a Winn's test and TD50 assay. Immunity against xenografts (TD50 assay) was significantly lower (by a factor of 2) in 4-week-old than in 12-week-old nude mice. Similarly, a significant 2-fold reduction in TD50 was obtained after a single intraperitoneal injection of cyclophosphamide into 8-week-old animals. Chronic (greater than 8 weeks) exposure of the nude mice to subcutaneously administered beta-estradiol markedly reduced the number of splenic NK cells and their cytolytic activity, but the TD50 reduction was not statistically significant (p = 0.1). Six Gray whole-body irradiations (WBI) had been shown to produce a highly significant, 3-fold reduction in the TD50 for FaDu. Flow cytometric analysis of splenic lymphoid cells from whole-body-irradiated recipients revealed: (a) marked initial depletion in the absolute numbers of lymphoid cells; (b) marked and long-lasting depletion of T cells, with slow and minimal recovery only evident between 6 and 12 weeks; (c) rapid, almost complete, depletion of B cells with prompt and partial recovery after 2 weeks; (d) depletion of NK cells and NK activity, with recovery by 10 weeks. No change in the number or phagocytic capacity of resident peritoneal macrophages was seen. These data give further support to a postulated role for residual T cells in the xenoreactivity of NCr/Sed nude mice.

Entities:  

Mesh:

Year:  1990        PMID: 2406204     DOI: 10.1002/ijc.2910450220

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Role of transfection and clonal selection in mediating radioresistance.

Authors:  F S Pardo; R G Bristow; A Taghian; A Ong; C Borek
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

2.  Irradiated compared with nonirradiated NSG mice for the development of a human B-cell lymphoma model.

Authors:  Deepti Chadalavada; Trinka W Adamson; John C Burnett; Robert W Chen; John J Rossi
Journal:  Comp Med       Date:  2014-06       Impact factor: 0.982

3.  Establishment and characterization of a prostate cancer cell line from a prostatectomy specimen for the study of cellular interaction.

Authors:  Ruoxiang Wang; Gina C-Y Chu; Xudong Wang; Jason B Wu; Peizhen Hu; Asha S Multani; Sen Pathak; Haiyen E Zhau; Leland W K Chung
Journal:  Int J Cancer       Date:  2019-05-10       Impact factor: 7.396

4.  Human immunodeficiency virus (HIV)-infected tumor xenografts as an in vivo model for antiviral therapy: role of alpha/beta interferon in restriction of tumor growth in nude mice injected with HIV-infected U937 tumor cells.

Authors:  P Puddu; C Locardi; P Sestili; F Varano; C Petrini; A Modesti; L Masuelli; I Gresser; F Belardelli
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

5.  Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.

Authors:  Ada H V Repetto-Llamazares; Roy H Larsen; Sebastian Patzke; Karianne G Fleten; David Didierlaurent; Alexandre Pichard; Jean Pierre Pouget; Jostein Dahle
Journal:  PLoS One       Date:  2015-06-11       Impact factor: 3.240

6.  Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib.

Authors:  Changhong Ke; Huan Hou; Jiayu Li; Kui Su; Chaohong Huang; Yue Lin; Zhiqiang Lu; Zhiyun Du; Wen Tan; Zhengqiang Yuan
Journal:  Cancers (Basel)       Date:  2020-05-04       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.